Hirdesh Uppal, Ph.D.

Hirdesh possesses over two decades of drug development expertise, making significant contributions advancing medicines from discovery to regulatory approval. In his recent role as VP of Development Sciences at CytomX Inc., he managed a diverse portfolio encompassing antibodies, ADC’s, bispecifics, and cytokines. Prior to this, he served as VP of Development Sciences at Revolution Medicines Inc., concentrating on novel therapies targeting RAS-addicted cancers. At Medivation Inc., Hirdesh led Translational Medicine & Companion Diagnostics (CDx), involving the translational strategy & clinical development for enzalutamide (XTANDIâ), talazoparib (TALZENNAâ) and several other pipeline molecules. He invented & facilitated successful clinical biomarker work culminating in CDx development at partner firms. His earlier tenure at Genentech Inc. and F. Hoffmann-La Roche Ltd focused on development sciences and safety assessment where he provided leadership & strategic alignment of a safety biomarker, stem cell & biochemical-molecular toxicology investigative laboratory group. Hirdesh holds a Ph.D. in Pharmacology from the University of Pittsburgh School of Medicine, a Doctor of Veterinary Medicine degree, and a Master’s in Immunology from Punjab Agricultural University, India. Additionally, he has completed Executive Management programs at the Stanford Graduate School of Business, Harvard Business School, and The Wharton School.